Simple Summary
Pleomorphic xanthroastrocytoma is a rare brain tumor that primarily affects children and young adults. Prediction of survival after diagnosis can be challenging due to the rarity of this tumor and the limited literature available to guide treatment decisions. In this study, we analyzed 597 patients with PXA to better understand how patient characteristics, tumor size, and treatment influence survival. We found that older age and larger tumors were associated with poorer survival outcomes. Using these findings, we developed an easy-to-use online tool that estimates a patient’s likelihood of survival at 5 and 10 years based on their individual characteristics. Our goal is to provide physicians and patients with a practical resource to better understand prognosis, guide discussions about treatment, and support more personalized care.
Abstract
Background: Pleomorphic xanthoastrocytoma (PXA) is a rare astrocytic neoplasm with variable clinical behavior. To better characterize survival outcomes and prognostic factors in patients with malignant PXA tumors, we performed a population-based analysis using data from the SEER program. Methods: We queried the SEER database using ICD-O-3 histology code 9424/3 to identify patients diagnosed with PXA between 2000 and 2022. Univariate and multivariable Cox regression were performed on demographic, tumor, and treatment variables to identify independent prognostic factors, with Kaplan–Meier Curves estimating survival for these same variables. To predict patient-specific 5- and 10-year survival probabilities, we built a web-based nomogram. Results: Overall survival rates of our 597 PXA patients were 92.2%, 86.7%, 81.5%, 74.6%, and 68.3% at 1-, 2-, 3-, 5-, and 10-years, respectively. In multivariable analysis, age ≥50 years was independently associated with significantly worse OS (p < 0.001). Larger tumor size (3.0–6.0 cm or >6 cm) also predicted poorer outcomes compared to smaller tumor size (<3.0 cm) (p < 0.01). When compared to patients who received gross total resection alone (GTR), patients who received GTR with chemotherapy and radiation, GTR with radiation, subtotal resection (STR) with chemotherapy and radiation, and STR with radiation all had worse OS (p < 0.01). Interestingly, patients who received STR alone had no statistically significant difference in OS compared to patients who received GTR alone (p > 0.05). Conclusions: We conducted the largest retrospective cohort study and provide the first nomogram-based app developed for PXA patients as a means of analyzing survival. Our aim for this app is to guide clinicians in more meaningful discussions with their patients and to provide an evidence-based tool that is easily deployable in the clinic.